Summary
Johnson & Johnson (JNJ) has announced the completion of its divestiture of the Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments. This strategic move marks a significant portfolio adjustment for JNJ, allowing the company to potentially streamline its operations and focus on core growth areas. The divested business, which generated around $1.9 billion in net sales in 2013, was a global provider of diagnostic solutions.
Key Highlights
- 1Completion of Ortho-Clinical Diagnostics divestiture for approximately $4 billion.
- 2Divestiture of a business that generated $1.9 billion in net sales in 2013.
- 3Sale to The Carlyle Group, a private equity firm.
- 4Transaction subject to customary purchase price adjustments.
- 5Financial impact of the divestiture will be discussed during the Q2 2014 earnings call on July 15, 2014.
- 6This divestiture represents a strategic sharpening of Johnson & Johnson's business portfolio.
Frequently Asked Questions
Johnson & Johnson divested its Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring, and confirming diseases.
The sale price was approximately $4 billion, subject to customary adjustments.
In 2013, the Ortho-Clinical Diagnostics business generated approximately $1.9 billion in net sales.
Johnson & Johnson plans to discuss the financial impact of this divestiture during its scheduled quarterly earnings call on July 15, 2014.